redhillbio.com - Multiplikator Forward P/S RDHL

Liquidity shortages and drug promotion costs are weighing on the budget of RedHill Biopharma (RDHL), which is why the company's forward P/S valuation, where GURU.Markets data informs this chart, has a current value of 0.30. Unique FDA-approved formulas provide stability, while growth prospects are based on the development of targeted antibiotics for the hospital sector and the treatment of gastrointestinal infections.
RedHill (RDHL) - rincian metrik lan laporan keuangan

The forward P/S ratio determines the market value of RedHill Biopharma (RDHL) relative to its projected annual revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the dynamics of the forward price-to-sales valuation, an investor can correlate market sales expectations for Talicia and Movantik with the success of clinical trials for oncology assets, which determines the fundamental stability of RedHill Biopharma (RDHL) within the biopharmaceutical sector.